Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

UBS Group upgraded shares of AstraZeneca (NASDAQ:AZN – Free Report) from a neutral rating to a buy rating in a research note ...

AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...

UBS has upgraded AstraZeneca (NASDAQ:AZN) to buy from neutral, stating it believes the company's in-market growth potential has been underestimated. The investment bank said its forecasts for the ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

AstraZeneca shares rose today after the drugmaker said it could face a fine of up to $4.5m in China over suspected unpaid ...